English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The inactivation of p16 INK4A  and p14 ARF  via promoter methylation has been investigated in various cancers. However, the clinical effects of p16 INK4A  and p14 ARF  promoter methylation on renal cell carcinoma (RCC) remain to be clarified. The pooled data were calculated and summarized. Finally, an investigation of 14 eligible studies with 1231 RCC patients and 689 control patients was performed. Methylated p16 INK4A  and p14 ARF  were observed to be significantly higher in RCC than in control subjects without malignancies (OR = 2.77, P = 0.005; OR = 11.73, P &lt; 0.001, respectively). Methylated p16 INK4A  was significantly associated with the risk of RCC in the tissue subgroup, but not in the serum and urine subgroups. Methylated p16 INK4A  was significantly associated with tumor size. We did not find that p16 INK4A  promoter methylation was associated with sex, tumor grade, lymph node status, and tumor histology. Methylated p14 ARF  was significantly correlated with sex and tumor histology. Three studies reported that p16 INK4A  methylation was not significantly correlated with the prognosis of RCC. The results suggested that p16 INK4A  and p14 ARF  promoter methylation may be correlated with the carcinogenesis of RCC, and that methylated p14 ARF  , especially, can be a major susceptibility gene. We also found the different clinicopathological significance of 16 INK4A  and p14 ARF  in RCC. Additional studies with sufficient data are essential to further evaluate the clinical features and prognostic effect of p16 INK4A  and p14 ARF  promoter methylation in RCC.

Clinical significance of p16INK4A and p14ARF promoter methylation in renal cell carcinoma: a meta-analysis